MEDIPOST Co., Ltd. (KOSDAQ:078160)

Market Cap	593.71B +96.1%
Revenue (ttm)	73.66B +4.2%
Net Income	-85.40B
EPS	-2,408.00
Shares Out	39.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	405,214
Average Volume	515,640
Open	15,050
Previous Close	15,190
Day's Range	13,690 - 15,050
52-Week Range	8,100 - 29,100
Beta	n/a
RSI	27.85
Earnings Date	Apr 3, 2026

About MEDIPOST

Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. It operates through the following business divisions: Cord Blood Bank, Stem Cell Therapy, Health Functional Food, Import and Distribution of Natural Cosmetics and Healthcare Services. The Cord Blood Bank division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapy division manufactures allogeneic stem cell drug products. The Health Functional Food division offers vitamins and nutritional supple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 078160

Financial Performance

In 2025, MEDIPOST's revenue was 73.66 billion, an increase of 4.25% compared to the previous year's 70.66 billion. Losses were -85.40 billion, 36.6% more than in 2024.